Tom 5, Nr 2 (2020)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2020-09-10
Wyświetlenia strony 1506
Wyświetlenia/pobrania artykułu 203
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Rekomendacje Polskiego Towarzystwa Ginekologów i Położników — zastosowanie antyseptyków w przypadkach nieswoistych stanów zapalnych pochwy

Mariusz Zimmer1, Hubert Huras2, Paweł Kamiński3, Agata Karowicz-Bilińska4, Krzysztof Drews5, Tomasz Fuchs1, Michał Pomorski1
Ginekologia i Perinatologia Praktyczna 2020;5(2):90-97.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Rekomendacje Polskiego Towarzystwa Ginekologicznego. Ginekol Pol. 2014; 85: 557–559.
  2. Bacterial Biofilms. Current Topics in Microbiology and Immunology. 2008.
  3. Weissenbacher ER, Donders G, Unzeitig V, et al. Fluomizin Study Group. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012; 73(1): 8–15.
  4. Menard JP. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. International Journal of Women's Health. 2011: 295.
  5. Sobczuk A, et al. Stany zapalne pochwy u kobiet w wieku menopauzalnym. Przegląd Menopauzalny. 2007; 3: 155–161.
  6. Pitsouni E, Grigoriadis T, Falagas M, et al. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017; 103: 78–88.
  7. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018; 25(1): 21–28.
  8. Alves P, Castro J, Sousa C, et al. Gardnerella vaginalis Outcompetes 29 Other Bacterial Species Isolated From Patients With Bacterial Vaginosis, Using in an In Vitro Biofilm Formation Model. The Journal of Infectious Diseases. 2014; 210(4): 593–596.
  9. Marchaim D, Lemanek L, Bheemreddy S, et al. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012; 120(6): 1407–1414.
  10. Verstraelen H, Verhelst R, Roelens K, et al. Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review. BMC Infectious Diseases. 2012; 12(1).
  11. Koban I, Bender CP, Assadian O, et al. Clinical Use of the Antiseptic Polihexanide for Genital Tract Infections. Skin Pharmacology and Physiology. 2012; 25(6): 298–304.
  12. Polyhexanide. Meyler's Side Effects of Drugs. 2016: 859.
  13. Allen M, White G, Morby A. The response of Escherichia coli to exposure to the biocide polyhexamethylene biguanide. Microbiology. 2006; 152(4): 989–1000.
  14. Hansmann F, Kramer A, Ohgke H, et al. Lavasept as an alternative to PVP-iodine as a preoperative antiseptic in ophthalmic surgery. Randomized, controlled, prospective double-blind trial. Ophthalmologe. 2005; 102(11): 1043–6, 1048.
  15. Rosin M, Welk A, Bernhardt O, et al. Effect of a polyhexamethylene biguanide mouthrinse on bacterial counts and plaque. Journal of Clinical Periodontology. 2001; 28(12): 1121–1126.
  16. Ikeda T, Ledwith A, Bamford CH, et al. Interaction of a polymeric biguanide biocide with phospholipid membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1984; 769(1): 57–66.
  17. Gabriel G, Som A, Madkour A, et al. Infectious disease: Connecting innate immunity to biocidal polymers. Materials Science and Engineering: R: Reports. 2007; 57(1-6): 28–64.
  18. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol. 2005; 99(4): 703–715.
  19. Kaehn K. Polihexanide: A Safe and Highly Effective Biocide. Skin Pharmacology and Physiology. 2010; 23(1): 7–16.
  20. Hübner NO, Kramer A. Review on the Efficacy, Safety and Clinical Applications of Polihexanide, a Modern Wound Antiseptic. Skin Pharmacology and Physiology. 2010; 23(1): 17–27.
  21. Ikeda T, Tazuke S, Watanabe M. Interaction of biologically active molecules with phospholipid membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1983; 735(3): 380–386.
  22. Ikeda T, Tazuke S, Bamford C, et al. Spectroscopic Studies on the Interaction of Polymeric In-chain Biguanide Biocide with Phospholipid Membranes as Probed by 8-Anilinonaphthalene-l-sulfonate. Bulletin of the Chemical Society of Japan. 1985; 58(2): 705–709.
  23. Pelletier C, Bouley C, Cayuela C, et al. Cell surface characteristics of Lactobacillus casei subsp. casei, Lactobacillus paracasei subsp. paracasei, and Lactobacillus rhamnosus strains. Appl Environ Microbiol. 1997; 63(5): 1725–1731.
  24. Charakterystyka wyrobu medycznego Infectvagin.
  25. Kramer A, Roth B, Müller G, et al. Influence of the Antiseptic Agents Polyhexanide and Octenidine on FL Cells and on Healing of Experimental Superficial Aseptic Wounds in Piglets. Skin Pharmacology and Physiology. 2004; 17(3): 141–146.
  26. Scambia G. Role of TIAGIN® vaginal formulation in cervical reepithelialszation and high-risk HPV clearance in patients with low-grade cervical lesions. Italian Journal of Gynaecology & Obstetrics. 2017; 1.
  27. Gentile A, et al. A new non-invasive approach based on polyhexamethylene biguanide increases the regression rate of HPV infection. BMC Clinical Pathology. 2012; 12(17).
  28. Kramer A, et al. Re-evaluation of polihexanide use in wound antisepsis in order to clarify ambiguities of two animal studies. Journal Of Wound Care. 2019; 28(4).
  29. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009; 27(1): 76–83.
  30. Charakterystyka produktu leczniczego Fluomizin.
  31. Petersen EE, Weissenbacher ER, Hengst P, et al. Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung. 2002; 52(9): 706–715.
  32. Mendling W, et al. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016; 293: 469–484.
  33. Charakterystyka produktu leczniczego Betadine.
  34. Kramer A, et al. Konsensus w sprawie antyseptyki ran: Aktualizacja 2018. Consensus Guidelines, Skin Pharmacol Physiol. 2018; 31: 28–58.
  35. Ricci C. Role of TIAGIN vaginal formulation in cervical reepithelialszation and high-risk HPV clearance in patients with low-grade cervical lesions. Italian Journal of Gynaecology & Obstetrics . 2017; 29(1).
  36. Rodriguez-Arguello J, Lienhard K, Patel P, et al. A Scoping Review of the Use of Silver-impregnated Dressings for the Treatment of Chronic Wounds. Ostomy Wound Manage. 2018; 64(3): 14–31.
  37. Mączyńska B, Junka A. Etiologia i patogeneza zakażeń pochwy u kobiet – srebro w cząsteczce TIAB jako alternatywna metoda leczenia infekcji. Okiem mikrobiologa. Forum Zakażeń. 2016; 7(3): 167–174.
  38. Homola W, et al. Rozwój metod screeningu, diagnostyki oraz postępowania z nieprawidłowym rozmazem cytologicznym. GinPolMedProject . 2019; 53(3): 33–38.
  39. Krakowiak W., Innowacyjna molekuła srebra TIAB w leczeniu zakażeń trudno gojących się ran. Biotechnologia.pl.
  40. Dębski R, Drews K, Paszkowski T, et al. Stanowisko Ekspertów na temat zastosowania wyrobu medycznego Hexatiab® Softgel w przypadkach infekcji pochwy. Ginekologia i Położnictwo. ; 2018(2): 12–15.
  41. Marquardt C, et al. Evaluation of the tissue toxicity of antiseptics by the hen’s egg test on the chorioallantoic membrane (hetcam). Eur J Med Res. 2010; 15: 204–209.
  42. Prutting SM, Cerveny JD. Boric acid vaginal suppositories: a brief review. Infect Dis Obstet Gynecol. 1998; 6(4): 191–194, doi: 10.1002/(SICI)1098-0997(1998)6:4<191::AID-IDOG10>3.0.CO;2-6.
  43. Sebastian F. Infectious Diseases in Obstetrics and Gynecology. 2008.
  44. Iavazzo C, Gkegkes ID, Zarkada IM, et al. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011; 20(8): 1245–1255.
  45. Charakterystyka produktu leczniczego Albivag.
  46. Mondello F, De Bernardis F, Girolamo A, et al. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect Dis. 2006; 6: 158.
  47. Charakterystyka wyrobu medycznego Chlorivag.
  48. Di Vi, Mattarelli P, Modesto M, et al. In Vitro Activity of Tea Tree Oil Vaginal Suppositories against Candida spp. and Probiotic Vaginal Microbiota. Phytother Res . 2015; 29(10): 1628–1633.
  49. Müller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother. 2008; 61(6): 1281–1287.
  50. Charakterystyka produktu leczniczego Gynoflor.



Ginekologia i Perinatologia Praktyczna